UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.